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Introduction
Recent worldwide cancer statistics, provided by GLOBOCAN 
2012,1 have shown that ~14.1 million people suffered from 
cancer in 2012. The number is expected to rise to 24 million 
in 20 years time.2 Some advances have been made in the iden-
tification of genes related to the cancer etiology. All these 
have led to the expansion of our understanding of the genetic 
mechanisms that are driving cancer progression. However, 
our knowledge is still very limited, and further research is 
needed in this field.
Recent improvements in molecular biology technology 
have allowed the measurement and profiling of DNA methy-
lation sites in large genomic samples.3 DNA methylation is an 
epigenetic mark that can provide information about environ-
mental exposures.4 Methylation occurs when a methyl group 
is added to a cytosine residue to convert it to 5-methylcytosine. 
It occurs at CpG sites, which are places on the linear sequence 
of the bases of the DNA that have a cytosine and guanine 
separated by only one phosphate. Methylation of sites that 
are in the promoters of genes can affect their expression 
and lead to their silencing, a feature found in a number of 
human cancers.5 Methylation is believed to be closely related 
to gene expression,6,7 and DNA methylation sites have been 
increasingly found to be related to the processes of cancer.8,9 
Methylation biomarkers have also been associated with the 
response of a patient to particular treatment of cancer as 
shown in some clinical studies.10,11
Machine learning has been widely used on biological data 
with increasing success.12–15 Methylation data, however, have 
only recently been analyzed using machine learning.16–18 Due 
to the high dimensionality of the methylation dataset, direct 
use of many machine learning methods is computationally 
intractable. The computational complexity of principal com-
ponents analysis (PCA) – the simplest and most fundamental 
method in multivariate data analysis – is at least n × n × D. 
Current methylation data may have in excess of 400,000 
probes (n) and perhaps 100 patient cases (D). The very large 
number of probes means that even PCA cannot be computed 
in practice. On our data sets attempts to compute PCA fea-
tures directly took several hours without yielding any result. 
Moreover, when the dimensionality of a dataset grows, there 
is an increasing difficulty in proving any result statistically 
Identifying Significant Features in Cancer Methylation  
Data Using Gene Pathway Segmentation
Zena m. Hira and Duncan f. Gillies
Department of Computing, Imperial College London, London, UK.
AbstrAct: In order to provide the most effective therapy for cancer, it is important to be able to diagnose whether a patient’s cancer will respond 
to a proposed treatment. Methylation profiling could contain information from which such predictions could be made. Currently, hypothesis testing 
is used to determine whether possible biomarkers for cancer progression produce statistically significant results. However, this approach requires the 
identification of individual genes, or sets of genes, as candidate hypotheses, and with the increasing size of modern microarrays, this task is becoming 
progressively harder. Exhaustive testing of small sets of genes is computationally infeasible, and so hypothesis generation depends either on the use of 
established biological knowledge or on heuristic methods. As an alternative machine learning, methods can be used to identify groups of genes that are 
acting together within sets of cancer data and associate their behaviors with cancer progression. These methods have the advantage of being multivari-
ate and unbiased but unfortunately also rapidly become computationally infeasible as the number of gene probes and datasets increases. To address this 
problem, we have investigated a way of utilizing prior knowledge to segment microarray datasets in such a way that machine learning can be used to 
identify candidate sets of genes for hypothesis testing.  A methylation dataset is divided into subsets, where each subset contains only the probes that 
relate to a known gene pathway. Each of these pathway subsets is used independently for classification. The classification method is AdaBoost with deci-
sion trees as weak classifiers. Since each pathway subset contains a relatively small number of gene probes, it is possible to train and test its classification 
accuracy quickly and determine whether it has valuable diagnostic information. Finally, genes from successful pathway subsets can be combined to create 
a classifier of high accuracy.
keywords: machine learning, methylation profiling, cancer progression
CItatIon: Hira and Gillies. Identifying Significant Features in Cancer Methylation Data 
Using Gene Pathway Segmentation. Cancer Informatics 2016:15 189–198  
doi: 10.4137/CIn.s39859.
tYPE: Methodology
RECEIvED: april 04, 2016. RESUbMIttED: June 19, 2016. aCCEPtED FoR 
PUblICatIon: July 03, 2016.
aCaDEMIC EDItoR: J. T. Efird, Editor in Chief
PEER REvIEw: Four peer reviewers contributed to the peer review report. Reviewers’ 
reports totaled 2,147 words, excluding any confidential comments to the academic editor.
FUnDInG: Authors disclose no external funding sources.
CoMPEtInG IntEREStS: Authors disclose no potential conflicts of interest.
CoRRESPonDEnCE: zena.hira09@imperial.ac.uk
CoPYRIGht: © the authors, publisher and licensee Libertas Academica Limited. This is 
an open-access article distributed under the terms of the Creative Commons CC-BY-NC 
3.0 License.
 Paper subject to independent expert blind peer review. All editorial decisions made 
by independent academic editor. Upon submission manuscript was subject to anti-
plagiarism scanning. Prior to publication all authors have given signed confirmation of 
agreement to article publication and compliance with all applicable ethical and legal 
requirements, including the accuracy of author and contributor information, disclosure of 
competing interests and funding sources, compliance with ethical requirements relating 
to human and animal study participants, and compliance with any copyright requirements 
of third parties. This journal is a member of the Committee on Publication Ethics (COPE).
 Published by Libertas Academica. Learn more about this journal.
Hira and Gillies
190 CanCer InformatICs 2016:15
significant, due to the sparsity of the meaningful data in the 
dataset in question. To overcome this, we put forward a new 
feature selection approach in which methylation data are com-
bined with prior knowledge obtained from biological pathways. 
Prior know ledge has been used before for the classification of 
cancer phenotypes from microarray gene expression data,19,20 
pathway information,21–26 or GO terms.27–30 Little has been 
done in terms of predicting response to cancer treatment 
using methylation data and prior knowledge. For our experi-
ments, we used pathway information from the ConsensusPath 
database (2015 release).31–34 The ConsensusPath database 
integrates different types of information, including protein 
interactions, genetic interactions signaling, metabolism, gene 
regulation, and drug target interactions in humans. These 
are taken from a number of databases, including Reactome, 
KEGG, HumanCyc, PID, and BioCarta. Pathways contain 
between 100 and 3000 genes in total and, therefore, can be 
analyzed using multivariate machine learning methods. It is 
feasible to analyze all the pathways in the consensus database 
in a short time. In our experiments, it took around 45 minutes 
to run the algorithm on all pathways on a single computer. The 
intuition behind our approach is that pathways represent sets 
of genes that are known to interact with each other in some 
way. We hypothesize that there is a better chance of finding a 
set of genes that may act together as a biomarker by searching 
pathway sets rather than searching random samples of genes. 
We do not expect to identify all the genes that could act as 
biomarkers for a particular disease. However, whenever we 
find a pathway set of genes with good predictive results we can 
analyze each gene individually to find out what contribution 
it makes as a biomarker and consequently build up a larger set 
of predictor genes. Eventually, the results may contribute to a 
better understanding of the mechanisms of cancer.
Materials and Methods
overview. Our method is illustrated in Figure 1. Complete 
methylation datasets are divided into subsets each containing 
exactly those genes that belong to a known pathway. Using the 
information in the ConsensusPath database,31–34 it creates 3213 
subsets mostly between 100 and 3000 genes each. Individual 
genes may appear in more than one pathway, and hence in 
more than one subset. As the number of genes on the pathways 
is relatively small, machine learning methods can be applied to 
them quickly using modest computing resources. Each subset 
is used individually to build a classifier for predicting response 
to treatment. We chose to use AdaBoost, with decision trees as 
weak classifiers, since boosting techniques can reduce the bias 
in supervised learning by being less susceptible to overfitting 
compared with other learning algorithms.35 The prediction 
accuracies of the resulting classifiers were tested for significance 
using z-scores and P values. We used randomly drawn sets of 
genes for these statistical tests. Our null hypothesis is that the 
genes belonging to the particular pathway under test are the 
better predictors of progression than a randomly selected set 
of genes. Finally, the most successful pathway sets were used 
to determine a single set of genes that can accurately classify 
the dataset. The genes with the highest Gini importance from 
each pathway set were selected. These genes were then added 
to a combined set. Several different thresholds for selecting 
the genes were investigated to find the combined set with best 
overall prediction accuracy.
The analysis was done using the Python programming 
language. The sklearn package was used for the machine 
learning algorithms. The rpy2 package was used for calling 
R code to map the methylation probes to pathways.
datasets. Two datasets were used in this study. The first 
was the Cancer Genome Atlas (TCGA) methylation brain 
lower grade glioma (LGG) dataset (http://cancergenome.nih.
gov/). In this, there are 370,203 probes and in total 531 sam-
ples. However, for many of these samples, there is no informa-
tion about the therapy outcome. In addition, some of the labels 
were not specific as to whether the patient has responded to 
treatment or not. Therefore, we chose to restrict our research 
to samples with the labels: complete remission/response and pro-
gressive disease. We used 82 samples, 57 of which were not 
responsive to treatment (progressive disease), while 25 were 
cases of complete remission. The samples that did not have any 
Figure 1. Pathway algorithm: in the first step the original methylation 
dataset is split into several smaller subsets in which all the genes of 
one subset belong to one pathway in the ConsensusPath database. 
AdaBoost is applied on the subsets to build classifiers for disease 
progression. The classification accuracy of each subset was calculated 
using stratified cross-validation to account for unbalanced classes. 
Randomly picked subsets of the probes in the original dataset were 
created so that the pathway sets with the highest accuracies could be 
tested for significance using z-scores and P values. 
notes: 1http://globocan.iarc.fr/Default.aspx. 6https://www.etriks.org/.
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information as to the progression of the disease were excluded 
from the analysis.
The second dataset was an as yet unpublished study of 
chronic myelogenous leukemia (CML) with 429,231 probes and 
91 samples. The data supplied for this research was fully anony-
mized. In this set, 60 samples were responsive to CML treat-
ment, while 31 samples were not. Other datasets from TCGA 
were unsuitable for analysis because of the problem of imbalance. 
The number of cases of non-responding patients was very small 
(only one or two samples), resulting in the classifier overfitting.
In this study, the relation between the different probe 
locations relative to each gene (island, shore, and shelf) was 
not investigated. Our objective was simply to identify sets of 
genes that can influence response. In the methylation data, 
there are many probes related to each individual gene. A map-
ping between genes and probes was provided with the CML 
data. Two different methods to find an aggregate response for 
each gene were investigated.
1. The corresponding CpG with the highest methylation 
value was chosen.
2. All the probes associated with the gene were used in 
the classifier.
Both methods identified the same sets of genes since 
probes that match to the same gene are correlated36 and deci-
sion trees use correlated features interchangeably. If the tree 
becomes repetitive, it gets pruned,37 so using all the probes 
can be much faster.
Theoretical background
Adaboost with decision trees as the weak classifiers. 
AdaBoost was used to make the classification of progression or 
nonprogression in our experiments. It is an ensemble method 
that combines a number of weak classifiers to provide accurate 
results. Each weak classifier can be thought of as an individual 
hypothesis about the data. New data are classified by aggregat-
ing the weak classifiers’ predictions. For ensemble methods to 
work as accurately as possible, the weak classifiers need to be 
diverse. Diversity means that they make different errors in the 
classification process.38 Normally, on successive training runs, 
the selection of the training data is adjusted to accommodate the 
most difficult cases.39 The classifiers are then combined using 
a method of aggregation such as voting to get a final strong 
classifier. The AdaBoost-SAMME algorithm40 was used. It 
is a multiclass version of the original algorithm, and decision 
trees were used as the weak classifiers. A decision tree takes 
input tuples of the form: (X, Y) = (x1, x2, …, xk, Y) and creates 
rules based on (x1, x2, …, xk), so that the target Y can be clas-
sified correctly. The tree is constructed by splitting the inputs 
recursively (recursive partitioning), and it ends when the subset 
at a node has items with the same label or when the accuracy, 
measured by the Gini impurity, can no longer be improved. 
The Gini impurity measures how often a random data point 
can be classified incorrectly if it was assigned to a random class 
based on the distribution of class labels of the whole set.
The Classification And Regression Tree41 algorithm was 
used in the decision trees, since it works with both categori-
cal and numerical target variables. It creates the tree with the 
features that give the biggest information gain at each node. 
Unlike other ensemble methods, AdaBoost does not have com-
plicated parameter settings. The only thing that needs to be 
chosen is the classifier (in this case decision trees) and the num-
ber of boosting rounds. We used ensemble methods since the 
size of the pathway set is variable. With ensemble methods, the 
size of the dataset does not matter since a number of classifiers 
are created and a majority vote is taken on them. Even if the 
size of the data is not sufficient (which can lead to overfiting), 
the majority vote on the classifiers will average out their predic-
tions.38 The sklearn implementation for AdaBoost42 was used 
in the experiments.
Logistic regression. Control experiments were carried 
out using logistic regression, in order to compare the perfor-
mance of our new method with the current state of the art. 
Logistic regression is widely used in biomedical data analysis. 
It calculates the logit transformation of the probability of the 
presence of the characteristic of interest. This is the relation-
ship between a binary categorical dependent variable and one 
or more independent variables (in this case continuous).
 
logit( ) ...P b b X b X b Xn n= + + + +0 1 1 2 2  (1)
where P is the probability of presence of the characteristic 
of interest.
stratified cross-validation. Cross-validation43 is a sta-
tistical method for calculating the accuracy of a model by 
assessing how well it generalizes over an independent dataset. 
It partitions the data into two groups, the training group and 
the validation group. The model is created using the train-
ing group and validated over the validation group. To reduce 
the variance, this process takes place in more than one round 
using different groups for training and validation. We have 
used stratified k-fold cross-validation, where the training and 
validation groups are selected so that the mean response val-
ues are approximately equal in all the folds. Since the clas-
sification is binary, each fold contains the same number of the 
two types of class labels.
z-score and P values. The z-score is a measurement of a 
sample’s relationship with a population mean. Using the stan-
dard normal distribution, it normalizes a group of data such 
that the mean is 0 and the standard deviation is 1. The z-score 
represents the distance between a sample’s raw score and the 
population’s mean in units of the standard deviation in the 
normalized distribution. The z-score is shown in equation 2, 
where µ is the mean and σ is the standard deviation.
 
z x= − µ
σ
 (2)
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The z-score is related to the P value. It is a measure of the 
probability that a sample does not belong to the population. 
Very high z-scores are associated with very small P values 
and are found in the tails of the normal distribution. Small 
P values indicate that it is very unlikely that the observed pat-
tern belongs to that distribution (null hypothesis). To check 
the significance of the P value, a confidence interval must be 
chosen. The 95% confidence interval consists of all values less 
than 1.96 standard errors away from the sample value. The 
obtained P value must be less than 0.05. Similarly, the 99% 
confidence interval consists of all values less than 2.58 stan-
dard errors away from the sample value, and the P value should 
be less than 0.01.
In order to provide a baseline for significance testing, sev-
eral random gene subsets were created. These were used to test 
the results obtained by our method against the null hypothesis 
that the same results could be obtained by a random selection 
of genes. The class distribution was the same in all random 
sets since the samples were left intact. The number of genes 
was different in every set, but each random sample was drawn 
following distribution of the number of genes in the pathway 
sets. This was to ensure a fair comparison.
results
Initially, as a control experiment, the complete datasets for 
LGG and CML were analyzed using conventional machine 
learning methods without pathway segmentation. PCA44 
was used for linear dimensionality reduction and manifold 
Isomap45 for nonlinear dimensionality reduction. It was not 
possible to obtain any results without using a dimensionality 
reduction method. The number of samples is far less than the 
number of features, and therefore, the covariance matrix will 
be singular and poorly estimated. Sample-by-sample affinity 
matrices, which contain similarity values for each sample pair, 
were used since gene-by-gene matrices were very large and even 
after several hours of computation did not yield any result. The 
affinity matrices were constructed using the covariances of the 
samples, and the dimensionality was equal to the number of 
samples. The results we obtained were not sufficiently accurate 
to make predictions as shown in Table 1, where the accuracy 
can be seen to be only slightly higher than the random (0.5) 
level. The receiver operating characteristic (ROC) curves are 
shown in Figure 2 for LGG and in Figure 3 for CML. The 
proximity of these two curves to the diagonal line, where the 
true positive results equal the true negative results, illustrates 
the lack of accuracy in these experiments. In the remainder of 
our experiments, the analysis was carried out on the raw data. 
PCA and Isomap were not used.
Analysis of the LGG dataset. Classification for LGG 
treatment response was performed on all pathway sets with 
a number of genes greater than 100. Gene sets with less than 
100 genes were discarded because of observed overfitting 
caused by insufficient information in the dataset for general-
ization. Four pathway sets that gave accuracy between 0.88 
and 0.90 were discovered. The accuracy, shown in Table 2, 
was estimated using 10-fold stratified cross-validation. The 
P values show that a null hypothesis that the results could 
be obtained by a random selection of genes can be rejected, 
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Figure 2. ROC curve for the prediction of disease progression using the 
complete LGG dataset.
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Figure 3. ROC curve for the prediction of disease progression using the 
complete CML dataset.
table 1. Accuracies obtained using the complete datasets with linear 
(PCA) and nonlinear (Isomap) forms of dimensionality reduction and 
AdaBoost.
DataSEt aCCURaCY vaRIanCE
CML with PCA 0.6044 0.0222
CML with Isomap 0.5155 0.0159
LGG with PCA 0.7083 0.0177
LGG with Isomap 0.6347 0.0289
note: The results are not significant.
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and we can conclude that the results are significant within 
the 99% confidence interval. Figure 4 shows the ROC curves 
for the four most successful pathway sets. Dimensionality 
reduction on those pathways worsens the results as shown in 
Supplementary File 1.
For comparison, Figures 5 and 6 show the ROC curves 
for two other pathway sets that do not perform so well when 
compared with the successful pantothenate and CoA biosyn-
thesis set. The accuracies for the same pathway sets found when 
logistic regression is applied instead of AdaBoost are given 
in Table 3. These results are not significant. The AdaBoost 
method performs better because the decision trees split the 
dataset several times instead of just once and because boosting 
methods tend to remove bias from the results.
Each gene was removed, in turn, from the best four path-
way sets to determine its contribution to the accuracy. After 
removal, the classification accuracy was recalculated using 
stratified cross-validation as described previously. Some genes 
have more effect than others and removing them affects the 
accuracy negatively. This is shown in Supplementary File 2.
Graphs of the highest scoring pathway compared against 
random gene sets are included in Supplementary File 3. For 
validation purposes, 980 random gene sets were generated, 
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Figure 4. ROC curves for the four pathway sets with the highest 
accuracy on the LGG dataset.
Receiver operating characteristic
1.0
1.0
0.8
0.8
0.6
0.6
Pantothenate and CoA biosynthesis (area = 0.93)
Retinoate biosynthesis II (area = 0.72)
T
ru
e 
p
o
si
ti
ve
 r
at
e
False positive rate
0.4
0.4
0.2
0.2
0.0
0.0
Figure 5. Comparison between pantothenate and CoA biosynthesis and 
retinoate biosynthesis II pathway sets.
table 2. Best performing pathway sets for LGG and their accuracies 
and variances using 10-K stratified cross-validation.
PathwaY aCCURaCY vaRIanCE z-SCoRE P-valUE
a 0.904 0.0191 3.9713 0.000036
B 0.891 0.0163 3.68249905 0.000116
C 0.890 0.0070 3.65034371 0.000131
D 0.879 0.0056 3.39268741 0.000346
abbreviations: Pathway A, pantothenate and CoA biosynthesis; pathway B, 
transcription factor creb; pathway C, pyrimidine metabolism; pathway D, IL2.
table 3. Accuracy results for logistic regression on the best LGG 
pathway sets.
PathwaY loGIStIC REGRESSIon
a 0.708
B 0.697
C 0.650
D 0.674
note: The pathways are the same as in Table 2.
having comparable sizes to the sets corresponding to the 
pathway subsets and allowing multiple runs of the significance 
tests. In 10 different runs, the accuracies of these random sets 
vary between 0.4 and 0.71, and the variance ranges between 
0.018 and 0.0287. The accuracy range can be seen to be far 
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Figure 6. Comparison between pantothenate and CoA biosynthesis and 
activation of Rac pathway sets.
Hira and Gillies
194 CanCer InformatICs 2016:15
lower than that of the best pathway sets (Table 2) and the 
variance is either equal to or much greater than the variance 
displayed by the pathway sets. These results show that the 
genes belonging to the pathway sets used in our method do 
play an important role in classifying cancer.
Gene set combination, LGG data. A set of genes with 
better discriminative properties was found by combining 
several successful pathway sets. This was done by observing 
closely how AdaBoost builds the decision classifiers. The fea-
tures (genes) that were important when building the deci-
sion trees were retained, and the remainder was filtered out. 
An important feature for a decision tree is one for which the 
weights are higher. This indicates how well the nodes of the 
decision tree are partitioned by that feature. The importance 
of a feature is related to its height in the tree with the root 
being the most important. This principle is also known as the 
Gini importance.
Several classifiers with different combinations of thresh-
old values were constructed, and the combination with the 
highest accuracy score was picked. The algorithm is shown 
in Figure 7. AccuracyThreshold had values between 0.7 and 0.9 
and GiniImportanceThreshold had different values ranging from 
0.003 to 0.5. Table 4 shows the resulting set of genes that can 
classify progression with an accuracy of 99%. Genes that have 
been previously associated with gliomas appear in bold. We 
also obtained the P value of this set, which is 0.00140625, 
showing that it is significant in the 99% confidence interval.
Analysis of the cML dataset. The pathway sets with the 
highest scores for the CML dataset are shown in Table 5. The 
P values show that the result is significant in the 99% confi-
dence interval. All the pathway sets were tested for their accu-
racy in predicting CML progression. There were two pathway 
sets that obtained an accuracy of 0.9888. These were the regu-
lation of KIT signaling (Fig. 8) and signaling events mediated by 
stem cell factor receptor (c-Kit) pathways, which had an identical 
ROC curve. Dimensionality reduction applied to these both 
linear and nonlinear once again worsens the results as shown 
in Supplementary File 1. The ROC curves for these two path-
ways are plotted in Figure 8. Examples of other pathway sets 
that do not perform so well are shown in Figures 9–11.
A control experiment was carried out to compare the use 
of logistic regression with AdaBoost. Is this correct? The results 
Figure 7. The gene selection algorithm based on accuracy thresholds 
and how important each feature is when constructing the decision tree.
table 4. The most discriminant genes for the LGG dataset.
SYMbol FUnCtIonal annotatIon
DDost Dolichyl-Diphosphooligosaccharide
PRKAR2B protein kinase, cAMP-dependent
PDPK1 3-phosphoinositide dependent protein kinase 1
PIK3CD phosphatidylinositol-4,5-bisphosphate 3-kinase
CDC16 cell division cycle 16
oat ornithine aminotransferase
KRaS Kirsten Rat Sarcoma Viral Oncogene Homolog
ntRK1 neurotrophic tyrosine kinase, receptor, type 1
nf1 neurofibromin 1
BTRC beta-transducin repeat containing E3 ubiquitin protein 
ligase
PIK3R3 phosphoinositide-3-kinase, regulatory subunit 3 (gamma)
KCNMB4 potassium large conductance calcium-activated 
channel, Mβ4
IfnGr1 interferon gamma receptor 1
SC5DL sterol-C5-desaturase
atF2 activating transcription factor 2
GABRB2 gamma-aminobutyric acid (GABA) A receptor, beta 2
StX1a syntaxin 1 A (brain)
GPX4 glutathione peroxidase 4
GAB2 GRB2-associated binding protein 2
EIF2AK1 eukaryotic translation initiation factor 2-alpha kinase 1
sos1 son of sevenless homolog 1 (Drosophila)
eXoC6 exocyst complex component 6
IRS1 insulin receptor substrate 1
ANK1 ankyrin 1, erythrocytic 2
IL6R interleukin 6 receptor
nrCam neuronal cell adhesion molecule
SLC22A2 solute carrier family 22 (organic cation transporter), 
member 2
PPCDC phosphopantothenoylcysteine decarboxylase
UPB1 ureidopropionase, beta
PTK2B protein tyrosine kinase 2 beta
ItGa2 integrin, alpha 2 (CD49B, alpha 2 subunit of VLA-2 
receptor)
Stat3 signal transducer and activator of transcription 3
SLCO4A1 solute carrier organic anion transporter family, 
member 4A1
SLCO2A1 solute carrier organic anion transporter family, 
member 2A1
 
table 5. Best performing pathway sets for CML and their accuracies 
and variances after 10-K stratified cross-validation.
PathwaY aCCURaCY vaRIanCE z-SCoRE P-valUE
a 0.9888 0.0011 6.44028444 ,0.00001
B 0.9888 0.0011 6.44028444 ,0.00001
C 0.8244 0.0176 2.11346295 0.0176
abbreviations: Pathway A, regulation of KIT signaling; pathway B, signaling 
events mediated by stem cell factor receptor (c-Kit); pathway C, superpathway 
of d-myo-inositol(1,4,5)-trisphosphate metabolism.
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for prediction accuracy are shown in Table 6. In all cases, logistic 
regression gave less accurate results. As described previously, 
individual genes were removed from the pathways to deter-
mine their effect on the accuracy. Some genes have more effect 
than others, and removing them affects the accuracy negatively. 
This is shown in Supplementary File 2.
Comparing the accuracy of all the random sets (shown in 
Supplementary File 3), after 10 different runs, we see that the 
accuracies vary between 0.4 and 0.7. Their variance is either 
equal to or much greater than the variance of the pathway 
sets. The variance of the two pathways is 0.0011, while for 
the random sets variance is between 0.0165 and 0.0260. The 
random pathways were used in order to calculate the z-score 
of the accuracy and the P values of the random sets compared 
to the two highest scoring pathways.
Gene sH2b3. Even though the purpose of this study was 
not to identify single genes, a single gene was found to have 
a significant effect. In the AdaBoost classifier models for the 
data, the probe that most of the modeling was based on was 
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Figure 8. ROC curve for the regulation of KIT signaling pathway set.
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Figure 9. Comparison between regulation of KIT signaling and arrestins 
in gpcr desensitization pathway sets.
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Figure 10. Comparison between regulation of KIT signaling and 
NF-kappa B signaling – Homo sapiens pathway sets.
table 6. Accuracy results for logistic regression applied to CML 
pathway sets.
PathwaY loGIStIC REGRESSIon
a 0.703
B 0.693
C 0.682
note: The pathways are defined in Table 5.
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Figure 11. Comparison between regulation of KIT signaling and 
acetylcholine synthesis pathway sets.
CpG cg00056489, which translates to gene SH2B3 or SH2B 
adaptor protein 3. Removing this gene only out of the pathway 
set reduced the classification accuracy to random (≈0.5) from 
the original 0.99 accuracy.
Gene set combination, cML data. Other genes in 
the whole dataset that have an important impact on the 
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classification are shown in Table 7. They were found by the 
same method used in the LGG data analysis. These genes can 
classify response to treatment with an accuracy of 0.94.
discussion
Four pathway sets were found that can classify progression 
and response to treatment for brain glioma accurately. All of 
them have previously been associated with gliomas and brain 
cancer. Pantothenate and CoA biosynthesis is related to brain 
neurodegeneration and iron accumulation in the brain.46 Stud-
ies have shown that the ratio between iron and zinc affects the 
malignancy of the tumor.47 Interleukin 2 was first used in the 
treatment of glioma in 1986 as a part of immunotherapy treat-
ments.48 Moreover, pyrimidine metabolism in human gliomas 
is increased by comparison to normal brain.49 The last pathway 
is related to the transcription factor creb. Transcription fac-
tor creb is shown to be overexpressed in gliomas,50 and it is 
related to their proliferation.51 In addition, a pathway set that 
had an accuracy of 0.85 is worth noting. This is the renal cell 
carcinoma pathway. It was shown that renal cell carcinoma is 
one of the most common sources of brain metastases.52 From 
the optimal set of genes that was found, response can be pre-
dicted very accurately (0.99). Some of the genes in the set have 
already been associated with gliomas.
For CML, we identified gene SH2B3 to be statistically 
related with the response to treatment. SH2B adapter protein 3 
is a protein that in humans is encoded by the SH2B3 gene.53,54 
Its role is to be involved in a range of signaling activities by 
growth factor and cytokine receptors. It is a member of the 
family of tyrosine kinase adapter proteins,1 the high-affinity 
cell surface receptors for many polypeptide growth factors, 
cytokines, and hormones,55 which are shown to be involved 
with the progression of many types of cancer. The possibil-
ity of manipulating receptor tyrosine kinase signaling in order 
to prevent cancer or enhance cancer therapy was explored 
previously.56 It is a key protein for the negative regulator of 
cytokine signaling and plays a critical role in hematopoiesis. 
Hematopoietic cells commonly related with leukemia.57,58 
Moreover, SH2B3 has already been identified as a predisposi-
tion gene to acute lymphoblastic leukemia.59
From the set of genes that was found to predict response 
very accurately (0.94), inositol polyphosphate-5-phosphatase 
has already been associated with leukemia.60 In addition, it is 
associated with SH2 since it encodes a protein in that domain. 
The protein is related to hematopoietic cells, and its move-
ment from the cytosol to the plasma membrane is mediated by 
tyrosine phosphorylation.61 Synaptojanin was also found in the 
set, which belongs to the inositol-polyphosphate 5-phosphatase 
family that has previously been associated with hairy cell 
leukemia, a chronic mature B-cell leukemia characterized by 
malignant B cells that have typical hairy protrusions.62
conclusion
We have devised a way of analyzing big microarray datasets by 
segmenting them using pathway information. Since the num-
ber of genes in a pathway is small, and therefore the corre-
sponding number microarray gene probes in a dataset is small, 
it is possible to apply modern machine learning methods, 
which are computationally infeasible with complete datasets, 
to any pathway subset. Our hypothesis is that we are more 
likely to find genes that are acting together in cancer among 
the genes belonging to a known pathway than in a randomly 
drawn set of genes. We have tested this hypothesis statistically 
and found that it is correct in two very large datasets.
Our work is primarily addressing the problems of apply-
ing machine learning to very large datasets. In this respect, 
we are aiming to develop methods that will assist biologists 
in their research. The aim of our work was not to produce a 
better list of biomarkers but to develop and validate a method 
of searching large dimensional datasets for information. The 
fact that some but not all of the genes identified in our studies 
have already been associated with the mechanisms of cancer is 
an encouraging validation of our approach.
Our results demonstrate the feasibility of the proposed 
method. For both the datasets analyzed, we could identify 
lists of genes that show a statistical association with response 
to treatment. Further experimentation, analysis, and clinical 
significance testing must be performed to determine whether 
these results can be used to define an effective biomarker for 
prediction of the progress of LGG and CML, and this can be 
done following current clinical practice.
Many further experiments with this technique could be 
carried out. We have used pathway data as our main source 
of prior knowledge, but there are other possibilities. Another 
possible source of information is the Molecular Signatures 
Database, which contains gene sets frequently used in gene 
set enrichment experiments. Our work does have common 
ground with gene set enrichment analysis, but a key difference 
is that rather than statistically associating a gene set with a 
phenotype, we are aiming to identify a set of genes providing 
accurate prediction of outcome. Our studies in this article have 
focused on methylation data since it has a very large number of 
probes. However, our method is completely general and could 
be used on any microarray experiments in the future.
table 7. The most discriminative genes for the CML data.
GEnE naME FUnCtIonal annotatIon
INPP5A Polyphosphate-5-phosphatase, 40kda
INPP5B Inositol polyphosphate-5-phosphatase, 75kda
IMPAD1 Inositol monophosphatase domain containing 1
INPP1 Inositol polyphosphate-1-phosphatase
INPP5J Inositol polyphosphate-5-phosphatase j
ITPKB Inositol 1,4,5-trisphosphate 3-kinase b
SH2B3 Sh2b adaptor protein 3
SYNJ2 Synaptojanin 2
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Although our results are encouraging, further work could 
be carried out to validate the method more thoroughly. However, 
there are problems associated with this. Our method carries out 
a guided search for a set of genes that will provide good predic-
tions of the prognosis of individual cancers. This means that we 
need labeled data for experimentation, and the results, based on 
cross-validation, apply primarily to the datasets used. Most pub-
licly available microarray sets have a small number of samples, 
meaning that proper validation requires testing a large number 
of these datasets. Currently, this is not possible due to the high 
human time cost in finding and curating the data for experiments. 
However, the European eTRIKS project6 is currently addressing 
the question of sharable, standardized biomedical data, and will 
shortly provide a platform on which our method could be tested 
automatically on very large volumes of data. We believe that many 
interesting discoveries will result from these tests.
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